150 related articles for article (PubMed ID: 31204944)
21. [Clinical Efficacy of Low-Dose Bortezomib-Based Triple Combination Therapy in the Treatment of Elderly Multiple Myeloma].
Chen YY; Li YH; Wang DM; Meng Z; Liu S; Guo SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):535-539. PubMed ID: 32319392
[TBL] [Abstract][Full Text] [Related]
22. The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen.
Pang Y; Shao H; Yang Z; Fan L; Liu W; Shi J; Wang Y; Han Y; Yang L
Front Oncol; 2020; 10():1617. PubMed ID: 32984029
[TBL] [Abstract][Full Text] [Related]
23. Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma.
Chen HF; Li ZY; Tang JQ; Shen HS; Cui QY; Ren YY; Qin LM; Jin LJ; Zhu JJ; Wang J; Ding J; Wang KY; Yu ZQ; Wang ZY; Wu TQ
Asian Pac J Cancer Prev; 2012; 13(9):4777-81. PubMed ID: 23167419
[TBL] [Abstract][Full Text] [Related]
24. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
[TBL] [Abstract][Full Text] [Related]
25. [A retrospective study of the BiRd regimen in the treatment of relapsed/ refractory multiple myeloma].
Liu XL; Li L; Shi QL; Chen LJ; Cao XX; Li J; Liao AJ; Zou DH; Sun JN; Gao SJ; Li W; Hou J; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):837-841. PubMed ID: 29166734
[No Abstract] [Full Text] [Related]
26. Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment.
Saeed N; Khan Z; Jehanzeb H; Shaikh T; Shaikh U; Adil SN; Madni V; Fatima H; Abiha UE; Ali N
Cureus; 2024 Apr; 16(4):e58999. PubMed ID: 38800157
[TBL] [Abstract][Full Text] [Related]
27. [Cost-Effectiveness Analysis of Different Chemotherapy Regimens in the Treatment of Patients with Multiple Myeloma].
Lai T; Zhao Q; Li F; Zhou XG; Song P; Wang LP; Mei JG; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):824-828. PubMed ID: 29950227
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
Liu Y; Ke XY; Wang J; Jing HM; Wang JJ; Dong F; Wan WL; Zhang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1628-32. PubMed ID: 25543487
[TBL] [Abstract][Full Text] [Related]
29. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
30. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma].
Xu YJ; Xia B; Wang L; Wang CY; Zhao HF; Yang HL; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1668-1674. PubMed ID: 30501702
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Wu XF; Li TT; Sun L; Wang LJ; Ran XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):894-898. PubMed ID: 32552954
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance].
Shen M; Huang ZX; Zhang JJ; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):131-136. PubMed ID: 33554809
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
[TBL] [Abstract][Full Text] [Related]
36. [Clinical Efficacy and Safety of R-CDOP Regimen for Treatment of Newly Treated DLBCL Patients with Adverse Prognostic Factors].
Yang FL; Shi ML; Wu XF; Qi JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1143-1148. PubMed ID: 31418370
[TBL] [Abstract][Full Text] [Related]
37. [Comparation of Clinical Efficacy between Two Regimens of Preexcitation Chemotherapy for MDS-RAEB Patients].
Pan PJ; Luo ZQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):515-519. PubMed ID: 30998163
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Efficacy of ALL-2005 and ALL-2009 Regimen and Factors Influencing Prognosis of Newly Diagnosed ALL Patients Aged between 10-18 Years Old].
Li X; Si SY; Cai JJ; Qu WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1904-1911. PubMed ID: 33283718
[TBL] [Abstract][Full Text] [Related]
39. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
40. [Maintenance therapies of thalidomine and interferon-α in multiple myeloma].
Li J; Cai JH; Huang BH; Liu JR; Zheng D
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(48):3417-20. PubMed ID: 22333255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
